Clinical significance of FBXW7 loss of function in human cancers

Fan, Jingyi; Bellon, Marcia; Ju, Mingyi; Zhao, Lin; Wei, Minjie; Fu, Liwu; Nicot, Christophe

doi:10.1186/s12943-022-01548-2

Molecular Cancer

Table 2 Most frequent FBXW7 mutations in human tumors

From: Clinical significance of FBXW7 loss of function in human cancers

Protein Change	Cancer Type	Mutation Type	Mutation Frequency	Sample Size
R14Q	Colon Adenocarcinoma	Missense	0.34	5120
X195_splice	Uterine Endometrioid Carcinoma	Splice	0.42	1078
X195_splice	Stomach Adenocarcinoma	Splice	0.31	1351
R224Q	Uterine Endometrioid Carcinoma	Missense	0.3	8236
G423V	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Missense	0.3	185
R441Q	Uterine Endometrioid Carcinoma	Missense	0.3	13882
R465C	Rectal Adenocarcinoma	Missense	0.43	1081
	Uterine Endometrioid Carcinoma	Missense	0.42	7291
	Stomach Adenocarcinoma	Missense	0.33	638
	Colon Adenocarcinoma	Missense	0.31	1119
R465H	Mucinous Adenocarcinoma of the Colon and Rectum	Missense	0.61	1622
	Uterine Endometrioid Carcinoma	Missense	0.44	1558
	Stomach Adenocarcinoma	Missense	0.43	2689
	Serous Ovarian Cancer	Missense	0.41	799
	Rectal Adenocarcinoma	Missense	0.39	9464
	Colon Adenocarcinoma	Missense	0.37	1208
R479G	Cervical Squamous Cell Carcinoma	Missense	0.6	167
R479G	Bladder Urothelial Carcinoma	Missense	0.41	165
R479L	Head and Neck Squamous Cell Carcinoma	Missense	0.62	257
R479P	Cervical Squamous Cell Carcinoma	Missense	0.33	162
R479Q	Uterine Endometrioid Carcinoma	Missense	0.6	1322
R479Q	Uterine Mixed Endometrial Carcinoma	Missense	0.45	816
R505C	Cervical Squamous Cell Carcinoma	Missense	0.53	296
	Uterine Endometrioid Carcinoma	Missense	0.48	4835
	Stomach Adenocarcinoma	Missense	0.43	1705
	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Missense	0.38	1512
	Esophageal Adenocarcinoma	Missense	0.38	1709
R505G	Endocervical Adenocarcinoma	Missense	0.75	1112
	Bladder Urothelial Carcinoma	Missense	0.61	416
	Colon Adenocarcinoma	Missense	0.5	117
	Lung Squamous Cell Carcinoma	Missense	0.33	335
	Cervical Squamous Cell Carcinoma	Missense	0.33	672
R505H	Uterine Endometrioid Carcinoma	Missense	0.54	450
R505H	Colon Adenocarcinoma	Missense	0.34	108
R505L	Head and Neck Squamous Cell Carcinoma	Missense	0.56	345
D520E	Uterine Endometrioid Carcinoma	Missense	0.41	7858
D520N	Bladder Urothelial Carcinoma	Missense	0.38	530
D520Y	Colon Adenocarcinoma	Missense	0.27	5120
Y545C	Breast Invasive Ductal Carcinoma	Missense	0.72	171
	Head and Neck Squamous Cell Carcinoma	Missense	0.43	79
	Uterine Endometrioid Carcinoma	Missense	0.4	63
	Uterine Endometrioid Carcinoma	Missense	0.36	498
S546L	Bladder Urothelial Carcinoma	Missense	0.76	1294
S582L	Rectal Adenocarcinoma	Missense	0.7	138
S582L	Colon Adenocarcinoma	Missense	0.4	169
R658*	Mucinous Adenocarcinoma of the Colon and Rectum	Nonsense	0.7	712
R658*	Rectal Adenocarcinoma	Nonsense	0.41	11437
	Uterine Endometrioid Carcinoma	Nonsense	0.37	6856
	Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor	Nonsense	0.21	10826
R658Q	Uterine Endometrioid Carcinoma	Missense	0.47	7801
	Colon Adenocarcinoma	Missense	0.41	2137
	Cervical Squamous Cell Carcinoma	Missense	0.41	1301
R689W	Colon Adenocarcinoma	Missense	0.37	176
	Uterine Endometrioid Carcinoma	Missense	0.36	12787

Based on the analysis of the TCGA database data displayed by cBioportal, we have categorized and summarized the most frequent mutations of FBXW7 and the cancer types in which the different types of mutations are most prevalent. The probability of mutation occurrence in each individual type of cancer (http://www.cbioportal.org/) is listed. The table indicates the nature of the mutation (missense, nonsense or splice defect). The sample size represents the number of tumors analyzed in search of a particular mutation.

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com